Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors

Study Summary

The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.

Conditions

Solid Tumors

Interventions / Drugs

mRNA-4157 Pembrolizumab SoC Treatment

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment161 participants

Primary Completion—

Lead SponsorModernaTX, Inc.

Data Retrieved2026-04-11 02:55:38.209239+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.